CTOs on the Move

Synchem

www.synchem.com

 
Synchem, Inc. is a Elk Grove Village, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.synchem.com
  • 1400 Chase Ave
    Elk Grove Village, IL USA 60007
  • Phone: 847.298.2436

Executives

Name Title Contact Details

Similar Companies

The Valens Company

The Valens Company (TSX:VLNS) (OTCQX:VLNCF) is a multi-licensed, vertically-integrated cannabis company focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and white-label product development. The Valens Company is the largest third-party extraction Company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. Additionally, our subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science.

PrimeGen Biotech

PrimeGen Biotech LLC is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kansas City University College of Dental Medicine

Kansas City University announced June 4 its plans to open a College of Dental Medicine on its Joplin, Missouri, campus, with an anticipated groundbreaking in 2020. The goal is to seat a class of 80 students in 2022.

Elevian

Elevian develops regenerative medicines that target root-cause aging mechanisms. We are a spin out from Harvard, led by a team of serial entrepreneurs and Harvard scientists.

NextCure

NextCure is a fully integrated biotechnology company discovering and developing first-in-class immunotherapy-based biologics for cancer and other diseases. The company is focused on understanding biological pathways and leveraging our FIND-IOTM technology to discover, validate and build a proprietary pipeline. We believe identifying and targeting immune pathways will promote identification of effective targets for mediating sustained immunity leading to improved outcomes for cancer patients.